

**Regd. Office :**  
'Zydus Tower',  
Satellite Cross Roads,  
Ahmedabad 380 015. India.  
Phone : +91-79-2686 8100 (20 Lines)  
Fax : +91-79-2686 2368  
www.zyduscadila.com  
CIN:L24230GJ1995PLC025878

<p>BSE Limited 1<sup>st</sup> Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u></p> <p><b>Kind Attn.:</b> Mr. Sanjay Golecha / Mr. Gopalkrishnan</p>	<p>National Stock Exchange of India Limited Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u></p> <p><b>Kind Attn.:</b> Famroze Pochara Asst. Vice President</p>
<p><b>Date:</b> August 11, 2017</p>	
<p><b>Re.:</b> Press Release</p>	

Dear Sir / Madam,

We enclose herewith a copy of press release dated August 11, 2017 titled "Zydus receives tentative approval from the USFDA for Mesalamine Suppositories for rectal use."

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,  
For, CADILA HEALTHCARE LIMITED

  
**UPEN H. SHAH**  
**COMPANY SECRETARY**



Encl.: As above

## **Zydus receives tentative approval from the USFDA for Mesalamine Suppositories for rectal use**

---

*Ahmedabad, 11 August 2017*

Zydus Cadila has received the tentative approval from the USFDA to market Mesalamine Suppositories for rectal use, 1000 mg. Mesalamine is used to treat an inflammatory bowel disease, such as ulcerative colitis. It will be produced at the group's Topical plant at Ahmedabad.

The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

\*\*\*